Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study.

Dousset, Léa; Pacaud, Alize; Barnetche, Thomas; Kostine, Marie; Dutriaux, Caroline; Pham-Ledard, Anne; Beylot-Barry, Marie; Gérard, Emilie; Prey, Sorilla; Andreu, Nicolas; Boniface, Katia; Seneschal, Julien

Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study.

Dousset, Léa; Pacaud, Alize; Barnetche, Thomas; Kostine, Marie; Dutriaux, Caroline; Pham-Ledard, Anne; Beylot-Barry, Marie; Gérard, Emilie; Prey, Sorilla; Andreu, Nicolas; Boniface, Katia; Seneschal, Julien.

Afiliación

Dousset L; Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France.
Pacaud A; Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France.
Barnetche T; Department of Rheumatology, National Reference Center for Severe Systemic Autoimmune Diseases, FHU ACRONIM, Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France.
Kostine M; Department of Rheumatology, National Reference Center for Severe Systemic Autoimmune Diseases, FHU ACRONIM, Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France.
Dutriaux C; Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France.
Pham-Ledard A; U1035 INSERM, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux University, Bordeaux, France.
Beylot-Barry M; Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France.
Gérard E; Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France.
Prey S; Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France.
Andreu N; Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France.
Boniface K; U1035 INSERM, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux University, Bordeaux, France.
Seneschal J; Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France.

JAAD Int ; 5: 112-120, 2021 Dec.

Article en En | MEDLINE | ID: mdl-34712997

Palabras clave

ICI, immune checkpoint inhibitor; OR, odds ratio; OS, overall survival; PD-1, programmed cell death-1; PFS, progression-free survival; aHR, adjusted hazard ratio; checkpoint inhibitors; halo phenomenon around cutaneous metastases; immunotherapy; irAE, immune-related adverse event; leukotrichia; melanoma; vitiligo

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: JAAD Int Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google